Drug intelligence / Profile preview

carboplatin + nab-paclitaxel + panitumumab

Development stage: Unknown
Lead developer: Johnson Matthey
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of carboplatin (a platinum-based chemotherapy agent), nab-paclitaxel (Abraxane, an albumin-bound form of paclitaxel), and panitumumab (Vectibix, a fully human monoclonal antibody targeting EGFR). This regimen combines conventional chemotherapy with targeted therapy to treat various cancers, particularly studied in HER2-negative inflammatory breast cancer. Nab-paclitaxel utilizes albumin-bound nanoparticles to enhance tumor drug delivery through receptor-mediated transport, while panitumumab blocks EGFR signaling to inhibit tumor growth and promote apoptosis.

Targets

EGFR (Epidermal growth factor receptor)MicrotubuleDNA

Beyond the preview

Go deeper on carboplatin + nab-paclitaxel + panitumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + nab-paclitaxel + panitumumab.

Explore the full profile